Skip to main content

NRIX

Stock
Health Care
Biotechnology

Performance overview

NRIX Price
Price Chart

Forward-looking statistics

Beta
0.90
Risk
65.58%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.

Company info

SectorHealth Care
IndustryBiotechnology
Employees292
Market cap$957.5M

Fundamentals

Enterprise value$345.3M
Revenue$56.4M
Revenue per employee—
Profit margin0.00%
Debt to equity5.54

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.79
Dividend per share—
Revenue per share$0.76
Avg trading volume (30 day)$9M
Avg trading volume (10 day)$9M
Put-call ratio—

Macro factor sensitivity

Growth-1.1
Credit+5.2
Liquidity-1.7
Inflation-3.6
Commodities+1.3
Interest Rates-1.6

Valuation

Dividend yield0.00%
PEG Ratio-4.58
Price to sales17.20
P/E Ratio-4.58
Enterprise Value to Revenue6.12
Price to book2.02

Upcoming events

Next earnings dayApril 9, 2025
Next dividend day—
Ex. dividend day—

News

Wall Street Analysts Predict a 143.41% Upside in Nurix Therapeutics (NRIX): Here's What You Should Know

The mean of analysts' price targets for Nurix Therapeutics (NRIX) points to a 143.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Investment Research (July 3, 2025)
Nurix Therapeutics (NRIX) Moves 14.2% Higher: Will This Strength Last?

Nurix Therapeutics (NRIX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Investment Research (June 3, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free